---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007574"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T12:56:18.737960+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Capricor Q1 net loss $24.4M; deramiocel BLA PDUFA Aug 31, 2025

## Summary
- Net loss of $24.4M ($0.53/sh) vs $9.8M loss ($0.31/sh) in Q1 2024; revenue $0 vs $4.9M.
- Cash and equivalents $144.8M as of Mar 31, 2025; expected to fund operations into 2027.
- FDA accepted BLA for deramiocel in DMD-cardiomyopathy with priority review; PDUFA date Aug 31, 2025.
- Mid-cycle review with FDA completed; no significant deficiencies identified; advisory committee planned.
- Appointed Dr. Michael Binks as CMO; NIAID plans to initiate StealthX vaccine Phase 1 trial in Q3 2025.

## SEC filing metadata
- accession: 0001558370-25-007574
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/0001558370-25-007574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007574
- JSON: https://secwatch.observer/filing/0001558370-25-007574.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.